Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus, a next-generation sequencing based companion diagnostic assay for PARP inhibitor therapies; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples. Novogene Co., Ltd. has a strategic partnership with Hummingbird Bioscience Pte. Ltd. to support the development of investigational drug candidate HMBD-001, an anti-HER3 antibody to be evaluated for treatment of various tumor types, including NRG1-fusion driven cancers. The company was founded in 2011 and is headquartered in Beijing, China.

Novogene Co., Ltd.

Novogene provides genomic services and solutions, leveraging next-generation sequencing (NGS) and bioinformatics expertise.

msh id	COM:NOVOGENE
symbol	688.32K
name	Novogene Co., Ltd.
homepage url	https://www.novogene.com
country	CN
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	2.14K
crunchbase url	-
linkedin url	-
founders	-

market cap	619.95M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.06
growth cost of revenue	-1
growth depreciation and amortization	-1.19
growth ebitda	-0.54
growth ebitda ratio	-0.56
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	1.35
growth gross profit ratio	1.26

6883

COM:NOVOGENE

Novogene

Last Close

13.56

22/11 06:45

Market Cap

4.43B

Beta: -

Volume Today

3.27M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	247.16M
cost of revenue	247.16M
depreciation and amortization	-4.76M
ebitda	24.83M
ebitda ratio	0.09
eps	0.06
eps diluted	0.06
operating expenses	247.16M
operating income	29.59M
operating income ratio	0.11

accounts receivables	-
capital expenditure	-16.13M
cash at beginning of period	114.27M
cash at end of period	95.59M
inventory	25.09M
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-